C
Clovis Oncology Inc
XETRA:C6O
Clovis Oncology Inc
XETRA:C6O
Price:
8.7
EUR
-10.66%
Market Cap:
€3B
Relative Value
There is not enough data to reliably calculate the relative value of C6O.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
C6O
Relative Value
Base Case
Not Available
Multiples Across Competitors
C6O Competitors Multiples
Clovis Oncology Inc Competitors
Clovis Oncology Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
Clovis Oncology Inc
XETRA:C6O
|
3B EUR | 26.4 | -14 | -17.4 | -16.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.5B USD | 6.6 | 167.4 | 16.2 | 23 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.2B USD | 5.3 | 25.5 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.1B USD | 6.3 | 22.5 | 15.3 | 15.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.1B USD | 10 | 32 | 23.5 | 24.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.6 | 17.7 | 13.1 | 15 | |
| AU |
|
CSL Ltd
ASX:CSL
|
78B AUD | 3.5 | 18.1 | 12.3 | 15.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.9B EUR | 14.2 | 33.4 | 56.9 | 58.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
